Nasdaq threatens radiology vendor with delisting from stock exchange
The Nasdaq is threatening radiology vendor Nanox Imaging with potential delisting from the stock exchange after it has failed to meet a key financial metric.
The Israel-based company—which has developed a commercial grade, tomographic imaging device with a digital X-ray source—revealed the news in a recent regulatory filing. Nanox received the notice from the stock exchange after the closing bid price for its shares fell below $1 for 30 consecutive business day.
It now faces a 180-day compliance period, until March 29, 2027, to right the ship. To regain compliance, the imaging vendor’s stock price must hit at least $1 for a minimum of 10 consecutive business days.
“The company intends to monitor the closing bid price of its ordinary shares and consider available options to regain compliance with the bid price requirement, but no decisions about a response have been made at this time,” Nanox said in a Sept. 28 filing with the U.S. Securities and Exchange Commission.
Nanox noted that it may be eligible for another extension, if it fails to meet the metric by March. As of Monday, the imaging vendor’s shares were trading at about $0.64 at the close of the market.
The company has faced multiple challenges in recent months leading up to the Nasdaq’s threat. Nanox reported its quarterly earnings in September, which included an estimated Q2 EBITDA loss of $11.3 million, up from $10.4 million during the same period in 2025. In June, Nanox also performed an “impairment assessment” of its assets. This was triggered by a “significant” decline in its stock price and reduced forecasted revenues and operating results. Nanox recorded an impairment charge of about $41 million, reducing the fair value of its intangible assets.
The same month, Nanox also raised concern about its continued viability amid persistent financial challenges. Nanox continues to be hampered by factors including manufacturing site readiness, construction and infrastructure completion, and regulatory processes. It also recently was sued by investors, who claim the company has made false and misleading claims about its business.
Along with manufacturing systems, Nanox also owns teleradiology firm USARad and AI-maker Zebra Medical, acquiring both in 2021 for over $200 million. The company also recently touted multiple wins, including inking a distribution agreement in Costa Rica.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.